Amgen (NASDAQ:AMGN) Issues Quarterly Earnings Results

Amgen (NASDAQ:AMGN) announced its earnings results on Thursday. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.76 by $0.20, Briefing.com reports. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. During the same quarter last year, the business earned $3.98 earnings per share. The company’s revenue for the quarter was up 22.0% compared to the same quarter last year. Amgen updated its FY24 guidance to $19.00 to $20.20 EPS.

Amgen Price Performance

Shares of AMGN opened at $311.29 on Friday. The firm has a 50-day simple moving average of $274.51 and a two-hundred day simple moving average of $281.33. The stock has a market cap of $166.97 billion, a PE ratio of 24.92, a P/E/G ratio of 2.68 and a beta of 0.60. Amgen has a 1-year low of $211.71 and a 1-year high of $329.72. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a $2.25 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 2.89%. Amgen’s payout ratio is currently 72.06%.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Oppenheimer reiterated an “outperform” rating and set a $350.00 price objective on shares of Amgen in a research note on Thursday, February 1st. StockNews.com raised Amgen from a “hold” rating to a “buy” rating in a research note on Friday. Barclays raised shares of Amgen from an “underweight” rating to an “equal weight” rating and lifted their target price for the stock from $230.00 to $300.00 in a research note on Friday. Leerink Partnrs cut shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Finally, Raymond James started coverage on shares of Amgen in a research report on Thursday, March 28th. They set a “market perform” rating on the stock. Ten equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $305.05.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the transaction, the senior vice president now owns 9,883 shares of the company’s stock, valued at approximately $3,094,268.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.46% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.